Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24.
A subtraction hybridization approach combined with a differentiation therapy model of human melanoma identified melanoma differentiation associated gene-7 (mda-7) as a gene upregulated during induction of terminal differentiation. Based on conserved structure, chromosomal location and cytokine-like properties, mda-7, has now been classified as a member of the expanding interleukin (IL)-10 gene family and designated as mda-7/IL-24. Extensive in vitro and in vivo human tumor xenograft studies confirm that mda-7/IL-24 induces apoptosis specifically in tumor cells without harming normal cells. Unique properties of mda-7/IL-24 action also include potent "bystander antitumor" activity, an ability to exert anti-angiogenic effects, immune modulating ability and a capacity to enhance the sensitivity of tumor cells to radiotherapy, chemotherapy and monoclonal antibody therapy. Very recent studies from our groups further reveal autocrine regulation and chemoprevention facilitating properties of mda-7/IL-24. Based on these remarkable antitumor attributes, mda-7/IL-24 was evaluated by intratumoral injection with a replication incompetent adenovirus expressing this gene (Ad.mda-7; INGN 241) in a phase I clinical trial in patients with metastatic melanomas and other advanced solid cancers. mda-7/IL-24 was well tolerated with significant clinical activity. This review highlights our current understanding of the molecular and biochemical basis of mda-7/IL-24 antitumor properties and highlights its potential as a viable gene-based therapy for a wide spectrum of primary and advanced cancers.
Emdad
Luni
L
Departments of Neurosurgery and Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA. Luni.Emdad@mountsinai.org
Lebedeva
Irina V
IV
Su
Zhao-zhong
ZZ
Gupta
Pankaj
P
Sauane
Moira
M
Dash
Rupesh
R
Grant
Steven
S
Dent
Paul
P
Curiel
David T
DT
Sarkar
Devanand
D
Fisher
Paul B
PB
D000818:Animals; D017209:Apoptosis / Q000235:genetics / Q000502:physiology*; D017321:Clinical Trials, Phase I as Topic; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007378:Interleukins / Q000235:genetics / Q000502:physiology*; D008545:Melanoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008954:Models, Biological; D016896:Treatment Outcome; D000099180:Interleukin-24
D007378:Interleukins; D000099180:Interleukin-24